ストックスクリーナーアプリを入手
1.26
5.88%
0.07
プレマーケット:
1.24
-0.02
-1.59%
前日終値:
$1.19
開ける：
$1.22
24時間の取引高:
782.56K
Relative Volume:
1.27
時価総額：
$56.18M
収益：
-
当期純損益:
$-40.56M
株価収益率:
-1.0769
EPS:
-1.17
ネットキャッシュフロー:
$-35.28M
1週間 パフォーマンス:
-5.97%
1か月 パフォーマンス:
-16.00%
6か月 パフォーマンス:
-58.00%
1年 パフォーマンス:
-73.47%
1日の値動き範囲:
$1.19
$1.305
1週間の範囲:
$1.16
$1.49
52週間の値動き範囲:
$1.16
$5.00
Pds Biotechnology Corporation Stock (PDSB) Company Profile
名前
Pds Biotechnology Corporation
セクター
電話
800-208-3343
住所
303A COLLEGE ROAD EAST, PRINCETON
PDSB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
1.26 | 56.18M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-11-01 | 開始されました | B. Riley Securities | Buy |
| 2021-06-28 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-11-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | 開始されました | Alliance Global Partners | Buy |
| 2020-03-09 | 開始されました | Noble Capital Markets | Outperform |
| 2019-10-24 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Pds Biotechnology Corporation (PDSB) 最新ニュース
PDS Biotechnology at Life Sciences Virtual Investor Conference: Strategic Advances in Cancer Treatment - Investing.com India
PDS Biotech receives FDA clearance to start clinical study on new treatment for metastatic colorectal cancer - Marketscreener.com
PDS Biotechnology Receives FDA Clearance for Versamune MUC1 Trial in Colon Cancer - Marketscreener.com
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer - The Manila Times
PDS Biotech Leadership to Participate in March Conferences - The Manila Times
PDS Biotechnology commences trial for head and neck squamous cell carcinoma - Yahoo
H.C. Wainwright maintains $21 target on PDS Biotech stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $21 target on PDS Biotech stock - Investing.com India
HC Wainwright Reiterates “Buy” Rating for PDS Biotechnology (NASDAQ:PDSB) - Defense World
PDS Biotech begins phase 3 trial for HPV cancer therapy By Investing.com - Investing.com Australia
PDS Biotech launches phase 3 trial for HPV cancer therapy By Investing.com - Investing.com Australia
PDS Biotech launches phase 3 trial for HPV cancer therapy - Investing.com India
PDS Biotech begins phase 3 trial for HPV cancer therapy - Investing.com India
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer - The Manila Times
Eli Lilly Pours $27B Into U.S. Growth—What It Means for Investors - The Globe and Mail
Understanding the Risks of Investing in PDS Biotechnology Corporation (PDSB) - Knox Daily
PDS Biotechnology’s Stephen Glover purchases $25,001 in common stock By Investing.com - Investing.com Canada
PDS Biotechnology director Gregory Freitag purchases $24,999 in stock By Investing.com - Investing.com Canada
PDS Biotechnology director Gregory Freitag purchases $24,999 in stock - Investing.com India
PDS Biotechnology’s Stephen Glover purchases $25,001 in common stock - Investing.com India
PDS Biotechnology Directors Increase Holdings with Recent Purchases - TradingView
PDSB stock touches 52-week low at $1.2 amid sharp annual decline By Investing.com - Investing.com South Africa
PDSB stock touches 52-week low at $1.2 amid sharp annual decline - Investing.com India
EMV Capital portfolio company PDS Biotechnology raises $11mln - Proactive Investors Australia
PDS Biotechnology Launches Registered Direct Offering; Shares Up -February 27, 2025 at 12:02 pm EST - Marketscreener.com
PDS Biotechnology Corp. to Host Earnings Call - ACCESS Newswire
PDS Biotech secures $11 million in direct offering By Investing.com - Investing.com South Africa
PDS Biotech secures $11 million in direct offering - Investing.com India
PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times
PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology - The Manila Times
Where Do Analysts Think The PDS Biotechnology Corporation (NASDAQ: PDSB) Is Going - Stocks Register
PDS Biotechnology (NASDAQ:PDSB) Given Buy Rating at HC Wainwright - Defense World
PDS Biotech stock plunges to 52-week low of $1.25 By Investing.com - Investing.com Nigeria
Do you want to know where to find good stock? Take a look at PDS Biotechnology Corporation’s (NASDAQ:PDSB) Sentiment Analysis – US Post News - US Post News
PDS Biotech stock plunges to 52-week low of $1.25 - Investing.com
PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research - The Manila Times
PDS Biotechnology Reports Promising Phase 2 Results for Versamune® HPV in Treating HPV16-Positive Cancers; Phase 3 Trial Planned for Q1 2025 - Nasdaq
Cancer Breakthrough? PDS Biotech's HPV Treatment Shows Perfect Survival Rate in Latest Trial - StockTitan
PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025 - The Manila Times
Can PDS Biotech's Latest Oncology Developments Transform Cancer Treatment? CEO to Reveal Strategy - StockTitan
PDSB stock touches 52-week low at $1.3 amid market challenges - MSN
Cancer Vaccines Market on Track for Major Expansion in the - GlobeNewswire
Cancer Vaccines Market on Track for Major Expansion in - One News Page
PDSB stock touches 52-week low at $1.3 amid market challenges By Investing.com - Investing.com South Africa
PDS Biotechnology (NASDAQ:PDSB) Trading Down 5.8%What's Next? - MarketBeat
Pds Biotechnology Corporation (PDSB) 財務データ
収益
当期純利益
現金流量
EPS
1.39%
0.55%
大文字化:
|
ボリューム (24 時間):